These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 31761448

  • 1. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI.
    Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
    [Abstract] [Full Text] [Related]

  • 2. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
    Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB.
    Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
    [Abstract] [Full Text] [Related]

  • 3. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW, Klempner SJ, Ou SI.
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [Abstract] [Full Text] [Related]

  • 4. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [Abstract] [Full Text] [Related]

  • 5. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, Camidge DR, Harding TC, Lanman RB, Simmons AD.
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J, French Cooperative Thoracic Intergroup (IFCT).
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [Abstract] [Full Text] [Related]

  • 10. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [Abstract] [Full Text] [Related]

  • 11. Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes.
    Ye L, Mesbah Ardakani N, Thomas C, Spilsbury K, Leslie C, Amanuel B, Millward M.
    Pathol Oncol Res; 2020 Oct; 26(4):2371-2379. PubMed ID: 32506395
    [Abstract] [Full Text] [Related]

  • 12. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y, Zhang FS, Guo L, Ying JM.
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec 08; 47(12):904-909. PubMed ID: 30522169
    [Abstract] [Full Text] [Related]

  • 13. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC, Chen ZH, Zhang XC, Xu CR, Yan HH, Xie Z, Chuai SK, Ye JY, Han-Zhang H, Zhang Z, Bai XY, Su J, Gan B, Yang JJ, Li WF, Tang W, Luo FR, Xu X, Wu YL, Zhou Q.
    EBioMedicine; 2019 May 08; 43():180-187. PubMed ID: 31027916
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC.
    Clin Lung Cancer; 2020 May 08; 21(3):e191-e204. PubMed ID: 31859066
    [Abstract] [Full Text] [Related]

  • 15. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland.
    Zhang W, Schmitz AA, Kallionpää RE, Perälä M, Pitkänen N, Tukiainen M, Alanne E, Jöhrens K, Schulze-Rath R, Farahmand B, Zong J.
    Acta Oncol; 2024 Jul 05; 63():542-551. PubMed ID: 38967220
    [Abstract] [Full Text] [Related]

  • 16. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.
    Lung Cancer; 2015 Sep 05; 89(3):357-9. PubMed ID: 26187428
    [Abstract] [Full Text] [Related]

  • 17. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.
    Oncologist; 2016 Feb 05; 21(2):156-64. PubMed ID: 26768482
    [Abstract] [Full Text] [Related]

  • 18. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
    Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X.
    Oncogene; 2020 Feb 05; 39(9):1846-1859. PubMed ID: 31754213
    [Abstract] [Full Text] [Related]

  • 19. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C, Zhang Z, Sun Y, Wang S, Wu M, Ou Q, Xu Y, Chen Z, Shao Y, Liu H, Hou P.
    J Transl Med; 2022 Sep 04; 20(1):390. PubMed ID: 36059009
    [Abstract] [Full Text] [Related]

  • 20. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
    McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.
    Clin Cancer Res; 2018 Jul 15; 24(14):3334-3347. PubMed ID: 29636358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.